Zealand Pharma A/S

Zealand Pharma A/S: Carbon Emissions and Climate Commitments

Zealand Pharma A/S, a biological product (except diagnostic) manufacturing company headquartered in Denmark, has reported its greenhouse gas (GHG) emissions for recent years. In 2025, the company's total GHG emissions were approximately 38.4 million kg CO2e. This total comprises approximately 72,000 kg CO2e from Scope 1 emissions and approximately 154,000 kg CO2e from Scope 2 emissions (market-based). Scope 3 emissions accounted for the largest portion, totalling approximately 38.1 million kg CO2e, with purchased goods and services representing a significant contributor.

For the reporting year 2024, Zealand Pharma reported total GHG emissions of approximately 27.7 million kg CO2e. Scope 1 emissions were around 131,000 kg CO2e, and Scope 2 emissions (market-based) were approximately 398,000 kg CO2e. Scope 3 emissions amounted to approximately 27.2 million kg CO2e, with purchased goods and services being the largest category.

In 2023, the company's total GHG emissions were approximately 25.6 million kg CO2e, with Scope 1 emissions at approximately 144,000 kg CO2e and Scope 2 emissions (market-based) at approximately 402,000 kg CO2e. Scope 3 emissions were approximately 24.3 million kg CO2e.

Zealand Pharma has established near-term science-based targets aligned with a 1.5°C warming scenario. The company commits to reducing its absolute Scope 1 and Scope 2 GHG emissions by 46.2% by 2031, using 2024 as a base year. Furthermore, Zealand Pharma aims to reduce its Scope 3 GHG emissions from investments by 55.8% per EUR value added within the same timeframe. The company also pledges that by 2029, 80.0% of its suppliers, based on emissions for purchased goods and services, will have science-based targets. Zealand Pharma is committed to achieving net-zero emissions.